Mpm Bioimpact
Mpm Bioimpact reported 36 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGEM (11.5%), AKTS (7.3%) and TVTX (4.9%). Compared with Q2 2026, the fund opened new positions in IOVA, IMCR and VIR, added to DYN, TSHA and ANL, trimmed CGEM, TVTX and EWTX and sold out of RVMD, ALMS and RARE.
Latest filing: what Mpm Bioimpact did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() CGEM Cullinan Therapeutics Inc | $149M | 11.5% | 9.7M | −10K (−0%) | 8 of 8 | |
| 2 | ![]() AKTS Aktis Oncology Inc | $94.2M | 7.3% | 4.8M | No change | 3 of 8 | |
| 3 | ![]() TVTX Travere Therapeutics Inc | $64.1M | 4.9% | 1.1M | −34K (−3%) | 3 of 8 | |
| 4 | ![]() EWTX Edgewise Therapeutics Inc | $64M | 4.9% | 1.6M | −45K (−3%) | 8 of 8 | |
| 5 | ![]() DYN Dyne Therapeutics Inc | $51.7M | 4.0% | 3.2M | +1.3M (+67%) | 6 of 8 | |
| 6 | ![]() CORT Corcept Therapeutics Inc | $48.6M | 3.7% | 422K | −349K (−45%) | 3 of 8 | |
| 7 | ![]() RLAY Relay Therapeutics Inc | $42.8M | 3.3% | 2.4M | −46K (−2%) | 8 of 8 | |
| 8 | ![]() TRVI Trevi Therapeutics Inc | $42.7M | 3.3% | 3M | −95K (−3%) | 8 of 8 | |
| 9 | ![]() IOVA Iovance Biotherapeutics Inc | $42M | 3.2% | 2.8M | New position | 3 of 8 | |
| 10 | ![]() LQDA Liquidia Corporation | $40.6M | 3.1% | 1.3M | −43K (−3%) | 5 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() RVMD Revolution Medicines Inc | $92.2M | 492K |
![]() ALMS Alumis Inc | $56.8M | 2M |
![]() RARE Ultragenyx Pharmaceutical in | $47.4M | 1.4M |
![]() DNTH Dianthus Therapeutics Inc | $40.9M | 420K |
![]() MLTX Moonlake Immunotherapeutics | $31.3M | 1.6M |
🔒 Free account: see all 10.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() CORT Corcept Therapeutics Inc | Put | $48.6M | 422K | +422,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Mpm Bioimpact 13F FAQ
What does Mpm Bioimpact own?
Mpm Bioimpact reported 36 stocks worth $1.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are CGEM (11.5%), AKTS (7.3%) and TVTX (4.9%). The table above lists every position in the filing (the top 10 without an account).
What did Mpm Bioimpact buy and sell in Q3 2026?
Compared with Q2 2026: 9 new positions, 8 added to, 18 trimmed and 10 sold out. New positions include IOVA, IMCR and VIR. It sold all of RVMD, ALMS and RARE.
When will Mpm Bioimpact file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Mpm Bioimpact's portfolio worth?
The Q3 2026 filing reports $1.3B in US stocks ($1.3B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.























